Abstract
NF-κB is an inducible transcription factor that is controlled by the signal activation cascades. NF-κB controls a number of genes involved in immuno-inflammatory responses, cell cycle progression, inhibition of apoptosis, and cell adhesion, thus promoting chronic inflammatory responses. In fact, NF-κB is constitutively activated in some rheumatic conditions such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Interestingly, a number of anti-RA compounds have been shown to exhibit anti-NF-κB activities. In addition, NF-κB activation has been linked to carcinogenesis and its constitutive activation has been demonstrated in some cancers and leukemias. These findings have substantiated the long-standing proposal of the link among chronic inflammation, autoimmunity, and carcinogenesis by molecular terms. In this review, I have attempted to overview the pathologic involvement of NF-κB in rheumatic diseases and discuss the feasibility of a therapeutic strategy with NF-κB and its signaling cascade as novel molecular targets.
Keywords: NF-κ B, signal transduction, IKK, transcription, apoptosis, inflammation, autoimmunity, rheumatoid arthritis, systemic lupus erythematosus, inhibitors
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: NF-κ B and Rheumatic Diseases
Volume: 6 Issue: 4
Author(s): Takashi Okamoto
Affiliation:
Keywords: NF-κ B, signal transduction, IKK, transcription, apoptosis, inflammation, autoimmunity, rheumatoid arthritis, systemic lupus erythematosus, inhibitors
Abstract: NF-κB is an inducible transcription factor that is controlled by the signal activation cascades. NF-κB controls a number of genes involved in immuno-inflammatory responses, cell cycle progression, inhibition of apoptosis, and cell adhesion, thus promoting chronic inflammatory responses. In fact, NF-κB is constitutively activated in some rheumatic conditions such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Interestingly, a number of anti-RA compounds have been shown to exhibit anti-NF-κB activities. In addition, NF-κB activation has been linked to carcinogenesis and its constitutive activation has been demonstrated in some cancers and leukemias. These findings have substantiated the long-standing proposal of the link among chronic inflammation, autoimmunity, and carcinogenesis by molecular terms. In this review, I have attempted to overview the pathologic involvement of NF-κB in rheumatic diseases and discuss the feasibility of a therapeutic strategy with NF-κB and its signaling cascade as novel molecular targets.
Export Options
About this article
Cite this article as:
Okamoto Takashi, NF-κ B and Rheumatic Diseases, Endocrine, Metabolic & Immune Disorders - Drug Targets 2006; 6 (4) . https://dx.doi.org/10.2174/187153006779025685
DOI https://dx.doi.org/10.2174/187153006779025685 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Targets in Infections with Ebola and Marburg Viruses
Infectious Disorders - Drug Targets Non-Analgesic Effects of Opioids: Opioids’ Effects on Sleep (Including Sleep Apnea)
Current Pharmaceutical Design Safety and Efficacy of Mavrilimumab For Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Current Rheumatology Reviews Medicinal Herbs with Anti-Inflammatory Activities for Natural and Organic Healing
Current Organic Chemistry Current and Future Pharmaceutical Therapy for Rheumatoid Arthritis
Current Pharmaceutical Design Vitiligo: Pathogenetic Hypotheses and Targets for Current Therapies
Current Drug Metabolism Current Status and Future Prospects for Research on Tyrosine Sulfation
Current Pharmaceutical Biotechnology The Evolving Therapy of Rheumatic Diseases, The Future is Now
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Development of Biodegradable Injectable In situ Forming Implants for Sustained Release of Lornoxicam
Current Drug Delivery Progress in Multiple Sclerosis Genetics
Current Genomics Histidine Hydrogen Bonding in MHC at pH 5 and pH 7 Modeled by Molecular Docking and Molecular Dynamics Simulations
Current Computer-Aided Drug Design Can We Delay the Accelerated Lung Aging in COPD? Anti-Aging Molecules and Interventions
Current Drug Targets Coronary Microvascular Dysfunction and Heart Failure with Preserved Ejection Fraction - implications for Chronic Inflammatory Mechanisms
Current Cardiology Reviews Alzheimer’s Disease-like Early-phase Brain Pathogenesis: Self-curing Amelioration of Neurodegeneration from Pro-inflammatory ‘Wounding’ to Anti-inflammatory ‘Healing’
Current Alzheimer Research Modulation of MMPs by Cell Surface Integrin Receptor α5β1
Anti-Cancer Agents in Medicinal Chemistry Update on the Rheumatologic Manifestations of Malignancy
Current Cancer Therapy Reviews Biologic Therapy in Psoriasis: Safety Profile
Current Drug Safety Cardio-Rheumatology: Two Collaborating Disciplines to Deal with the Enhanced Cardiovascular Risk in Autoimmune Rheumatic Diseases
Current Vascular Pharmacology Biologic Therapy in Inflammatory Eye Conditions (Ophtalmology): Safety Profile
Current Drug Safety Assessment of Inflammatory Response and its Resolution in Viral Infection and Rheumatoid Arthritis
Current Pharmaceutical Design